Clinical trials: Flu
Influenza
Influenza Immunity Against Pandemic Respiratory Virus
Sixty adults, ages 18-49, will be randomly assigned to receive either FluMist or Fluzone. Some of the subjects will have participated in previous studies for these 2 vaccines.
- Trial name
- NCT00138281
- Testing
- FluMist, Fluzone
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
The hypothesis for this trial is that the incidence of a pre-defined composite of common systemic hypersensitivity adverse events for Flublok recipients is non-inferior to that reported for licensed IIV recipients.
- Trial name
- NCT01825200
- Testing
- Flublok, Afluria
- Where
- 14 sites in United States
- Volunteers
- 2,640 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02831751
- Testing
- 30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain)
- Where
- 15 sites in United States, Canada
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Medicago
H7N9 Influenza Vaccine
A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects
This study aims to evaluate the safety and immunogenicity of an inactivated cell culture derived H7N9 vaccine in healthy adult subjects.
- Trial name
- NCT02436928
- Testing
- AT-501 High Dose vaccine, AT-501 High Dose vaccine with Adjuvant, AT-501 Low Dose vaccine
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Immunization, Human Influenza
Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization
The purpose of this study is to determine whether Yili Lactoferrin ShuHua Milk are effective in reducing the occurrence of flu symptoms.
- Conditions
- Immunization, Human Influenza, Common Cold
- Trial name
- NCT01677702
- Testing
- Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml), Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml), Recombined low protein milk
- Where
- 2 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Inner Mongolia Yili Industrial Group Co., Ltd
Impact of Vaccination
Intranasal LAIV Mucosal Immunity Examination
The research of the investigators is focused on the understanding how the immune system functions and responds to intranasal vaccines.
- Trial name
- NCT07093281
- Testing
- Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Influenza
Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)
The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza…
- Trial name
- NCT02141581
- Testing
- Fluzone® (IM), Fluzone® Intradermal (ID), 2011-2012 FluMist®
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Stanford University
Avian Influenza, Influenza
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults
This is a Phase I randomized, double-blind, controlled trial in 275 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT02624219
- Testing
- AS03, MF59 adjuvant, Monovalent Influenza A/H5N8 vaccine
- Where
- 4 sites in United States
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Immunogenicity and Safety of GSK Biologicals' FluLaval® TF
The present study is intended to assess a novel formulation of FluLaval. The idea is to obtain preliminary data on the safety and immune response to the FluLaval TF influenza vaccine in adults.
- Trial name
- NCT00727428
- Testing
- FluLaval® TF
- Where
- Belgium
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic Influenza
A/H5N1 Dose Ranging Study With Adjuvant Patch
This is a Phase 1/2, randomized, observer-blind, placebo-controlled clinical trial. A maximum of 500 eligible subjects in 10 groups will be enrolled, randomized and vaccinated in this study.
- Trial name
- NCT00532792
- Testing
- A/H5N1
- Where
- 5 sites in United States
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Influenza
Bone Marrow and Peripheral Blood Immune Responses Study
The purpose of this study is to evaluate the immune response of the killed flu vaccine in healthy subjects. Participants in this study are considered to be healthy volunteers.
- Trial name
- NCT05616546
- Testing
- Influenza Vaccine
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Emory University
Human Influenza
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
To evaluate the safety of a single intramuscular (IM) injection of trivalent nonadjuvated influenza study vaccine, formulation 2012/2013, in adult and elderly subjects and the antibody response to each influenza vaccine antigen…
- Trial name
- NCT01636102
- Testing
- Trivalent influenza virus vaccine (TIV)
- Where
- Belgium
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Human
Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)
As yet the investigators do not understand if there are biomarkers of immune protection after the Flumist or Live Attenuated Flu Vaccine (LAIV).
- Trial name
- LAIV (NCT04080245)
- Testing
- Treatment Group Live Attenuated Flu Vaccine (LAIV)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Prevention of Influenza
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
- Trial name
- NCT07133802
- Testing
- Test Group
- Volunteers
- 6,680 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Influenza
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
The purpose of this study was to determine the safety and descriptive immunogenicity of the H1N1 influenza vaccine in healthy children.
- Trial name
- MI-CP217 (NCT00946101)
- Testing
- MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]
- Where
- 16 sites in United States
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
The primary objective of the study was to provide sera (collected from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to the Center for Biologics Evaluation and Research (CBER) for…
- Trial name
- GRC00097 (NCT04109222)
- Testing
- Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Avian Influenza
Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine
This study aim to compare immunogenicity of the inactivated H5 influenza vaccine single dose between subjects previously vaccinated with LAIV H5N2 and naïve subjects
- Trial name
- NCT02229357
- Testing
- OrniFlu® inactivated vaccine
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mahidol University
COVID -19, COVID - 19
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up.
- Conditions
- COVID -19, COVID - 19, COVID 19, Influenza
- Trial name
- CIRV2 (NCT07287137)
- Testing
- Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Influenza, Seasonal Influenza
Yearly Strain Variation Study, 2009/2010
The purpose of this study is to verify the immunogenicity and tolerance of a trivalent seasonal influenza vaccine with strain composition according to World Heath Organization/European Union (WHO/EU) recommendation for the…
- Trial name
- NCT00943657
- Testing
- Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]
- Where
- Austria
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Tuberculosis
Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine
The study is a single centre, phase I, double-blind, randomized, placebo-controlled trial that explored the safety and immunogenicity of 2 doses (Day 1 and Day 21) TB/FLU-04L tuberculosis vaccine versus matched placebo in…
- Trial name
- NCT02501421
- Testing
- tuberculosis vaccine
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Research Institute for Biological Safety Problems
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.